tbuckley/cabot-search huggingface dataset:
Association of Visit-to-Visit Variability of Systolic Blood Pressure With Cardiovascular Disease and Mortality in Primary Care Chinese Patients With Type 2 Diabetes—A Retrospective Population-Based Cohort Study
Authors: Eric Yuk Fai Wan, Colman Siu Cheung Fung, Esther Yee Tak Yu, Daniel Yee Tak Fong, Julie Yun Chen, Cindy Lo Kuen Lam
Journal: Diabetes Care (2016)

This study aimed to evaluate the impact of visit-to-visit variability (VVV) of systolic blood pressure (SBP) on cardiovascular disease (CVD) and mortality among primary care Chinese patients with type 2 diabetes mellitus (T2DM).A retrospective cohort study was conducted in 124,105 Chinese adult primary care patients with T2DM and without prior diagnosed CVD from August 2008 to December 2009. The VVV of SBP was evaluated using SDs of SBP over 24 months. The risks of CVD and all-cause mortality associated with variability in SBP were evaluated using Cox proportional hazards regression. Subgroup analysis was conducted by the stratification of age, sex, duration of diabetes, the presence of chronic kidney disease, baseline SBP and trend, and the number and class of antihypertensive drugs.A positive linear relationship between the VVV of SBP and the first incidence of CVD and all-cause mortality was identified over a median follow-up time of 39.5 months. Patients with a low SD of SBP of <5 mmHg had the lowest risks of CVD and all-cause mortality, and patients with an SD of SBP of ≥10 mmHg had significantly higher risks. For every 1 SD increase in the SD of SBP, the risks of CVD, all-cause mortality, and the composite of both events increased by 2.9% (95% CI 2.4-3.4%), 4.0% (95% CI 3.5-4.6%), and 3.4% (95% CI 3.0-3.8%), respectively. A direct linear relationship was also observed in all selected subgroups.SBP variability, irrespective of the mean SBP level, is a potential predictor for the development of CVD and all-cause mortality in patients with diabetes. In addition to monitoring BP targets for their patients with diabetes, clinicians should also remain vigilant about the visit-to-visit fluctuation of BP.
Haploidentical Allogeneic Hematopoietic Cell Transplantation in Adults with CD3/CD19-Depleted Grafts after Reduced-Intensity Conditioning: A Phase I/II Study.
Authors: Wolfgang A. Bethge, Martin Bornhaeuser, Dietrich W. Beelen, Gernot Stuhler, Matthias Stelljes, Rainer Schwerdtfeger, Christoph Faul, Wichard Vogel, Rupert Handgretinger, Lothar Kanz
Journal: Blood (2007)
Nurses and Clinical Research Coordinators (CRCs) collaboration to improve quality in clinical trials
Authors: A. Zeneli, P. Serra, T. Rosanna, B. Marina, D. Andreis, O.R. Arjocan, V. Gallà, M. Golinucci, F. Fabbri, P. Braghesiu, G. Gentili, V. Zavoiu, C. Nanni, M. Monti, A. Filograna, T. Fiumicelli, A. Ragazzini, F. Beniamino, S. Testoni, I. Barlati, O. Nanni
Journal: Annals of Oncology (2015)
Novel Combination of Gallium Nitrate, Rituximab and Dexamethasone for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Transformed Follicular Lymphoma.
Authors: Scott E. Smith, Patrick J. Stiff, Tulio Rodriguez, Amir Toor, Jared Klein
Journal: Blood (2005)
Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse
Authors: Tadashi Ashizawa, Akira Iizuka, Chizu Nonomura, Ryota Kondou, Chie Maeda, Haruo Miyata, Takashi Sugino, Koichi Mitsuya, Nakamasa Hayashi, Yoko Nakasu, Kouji Maruyama, Ken Yamaguchi, Ikumi Katano, Mamoru Ito, Yasuto Akiyama
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Humanized mouse models using NOD/Shi-scid-IL2rγnull (NOG) and NOD/LtSz-scid IL2rγnull (NSG) mouse are associated with several limitations, such as long incubation time for stem cell engraftment and the development of xenograft versus host disease in mice injected with peripheral blood mononuclear cells (PBMCs). To solve problems, we used humanized major histocompatibility class I- and class II-deficient NOG mice (referred to as NOG-dKO) to evaluate the antitumor effect of anti-programmed death-1 (PD-1) antibody. Experimental Design: Humanized NOG-dKO mice, in which human PBMCs and human lymphoma cell line SCC-3, or glioblastoma cell line U87 were transplanted, were used as an immunotherapy model to investigate the effect of anti-PD-1 antibody. A biosimilar anti-PD-1 mAb generated in our laboratory was administered to humanized NOG-dKO mice transplanted with tumors. Results: Within 4 weeks after transplantation, human CD45+ cells in antibody-treated mice constituted approximately 70% of spleen cells. The injection of anti-PD-1 antibody reduced by more 50% the size of SCC-3 and U87 tumors. In addition, induction of CTLs against SCC-3 cells and upregulation of natural killer cell activity was observed in the antibody-treated group. Tumor-infiltrating lymphocyte profiling showed that more exhausted marker (PD1+TIM3+LAG3+) positive T cells maintained in anti-PD-1 antibody–treated tumor. A greater number of CD8+ and granzyme-producing T cells infiltrated the tumor in mice treated with the anti-PD-1 antibody. Conclusions: These results suggest that NOG-dKO mice might serve as a good humanized immunotherapy model to evaluate the efficacy of anti-PD-1 antibody prior to the clinical treatment. Clin Cancer Res; 23(1); 149–58. ©2016 AACR.
High Dose Therapy with Autologous Blood Stem Cell Transplantation (ASCT) for Follicular Lymphoma: Long-Term Outcome According to Histologic Grade.
Authors: Brad Pohlman, Tony Jin, Kristie Summers, Elizabeth Kuczkowski, Matt Kalaycio, Ronald Sobecks, Steven Andresen, Laura Bernhard, Kelly Cherni, Janet Baker, Jennifer Bates, Brian J. Bolwell
Journal: Blood (2004)
Small Molecule SHIP Agonist AQX-MN100 Inhibits Multiple Myeloma (MM) Cell Growth In NOD/SCID Mice and Reduces Immune Suppressive Myeloid Derived Suppressor Cells (MDSC) and Regulatory T Cells (Tregs) In Mouse Model
Authors: Alice Mui, Mike Kennah, Christopher Ong, Raymond Anderson, Heather Sutherland
Journal: Blood (2010)
Imaging the Acute Formation of a Cortical Microbleed in Cerebral Amyloid Angiopathy
Authors: Gregoire Boulouis, Andreas Charidimou, Susanne Van Veluw, Steven M. Greenberg
Journal: JAMA Neurology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
The KIT Tyrosine Kinase Inhibitor Midostaurine (PKC412) Exhibits a High Response Rate in Aggressive Systemic Mastocytosis (ASM): Interim Results of a Phase II Trial.
Authors: Jason Gotlib, Tracy I. George, Chris Corless, Andrea Linder, Alisa Ruddell, Cem Akin, Daniel J. DeAngelo, Ilana Kepten, Carlo Lanza, Heidrun Heinemann, Ophelia Yin, Neil Gallagher, Tim Graubert
Journal: Blood (2007)
Obesity and Risk of Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study
Authors: Marianna Thordardottir, Sigrun Helga Lund, Ebba K Lindqvist, Rene Costello, Debra Burton, Neha Korde, Sham Mailankody, Gudny Eiriksdottir, Lenore J Launer, Vilmundur Gudnason, Tamara B Harris, Ola Landgren, Sigurdur Y Kristinsson
Journal: Blood (2014)
Pillar-1: Multicenter Phase 2 Study of Everolimus for Patients with Mantle Cell Lymphoma Who Are Refractory or Intolerant to Bortezomib.
Authors: Michael Wang, Leslie Popplewell, Robert H. Collins, Jane N. Winter, Andre Goy, Anna Robeva, Nicoletta Pirotta, Jenna Fan, Judith Klimovsky, Owen A. O'Connor
Journal: Blood (2012)
The Spectrum and Prognostic Relevance of Additional Abnormalities, Involving 12p and 21q, in Children with ETV6-RUNX1 Positive Acute Lymphoblastic Leukaemia (ALL)
Authors: Anthony V Moorman, Zoe J Konn, Kerry E Barber, Sarah L Wright, Adam RM Stewart, Helen Parker, Sue M Richards, Sally E Kinsey, Osborn B Eden, Ajay J Vora, Christopher D Mitchell, Jonathan C Strefford, Christine J Harrison
Journal: Blood (2008)
Dendritic Cell Reconstitution Following Autologous Stem Cell Transplant with GM-CSF Support for Multiple Myeloma.
Authors: Annette J. Schlueter, Judith K. Glasgow, Werner Wilke, Jacquie R. Marietta, Raymond J. Hohl, Thomas H. Carter, Roger D. Gingrich, Margarida D. Magalhaes-Silverman
Journal: Blood (2007)
Axillary Nodal Management Following Neoadjuvant Chemotherapy
Authors: Melissa Pilewskie, Monica Morrow
Journal: JAMA Oncology (2016)

The increasing use of neoadjuvant chemotherapy (NAC) for operable breast cancer has raised questions about optimal local therapy for the axilla.Sentinel lymph node biopsy (SLNB) after NAC in patients presenting with clinically negative nodes has an accuracy similar to upfront SLNB and reduces the need for axillary lymph node dissection compared with SLNB prior to NAC. In patients presenting with node-positive disease, clinical trials demonstrate that SLNB after NAC is accurate when 3 or more sentinel nodes are obtained, but long-term outcomes are lacking. The relative importance of pre- and post-NAC stage in predicting risk of locoregional recurrence remains an area of controversy.Neoadjuvant chemotherapy reduces the need for axillary lymph node dissection, and SLNB is an accurate method of determining nodal status after NAC.
Effects of Methionine Synthase (MS) A2756G and Methionine Synthase Reductase (MSR) A66G Polymorphisms on Methionine Metabolism in Brazilian Pregnant Women and Their Neonates.
Authors: Patricia R. Barbosa, Sally P. Stabler, Mario H. Hirata, Rosario D.C. Hirata, Robert H. Allen, Luiz F. Sampaio-Neto, Elvira M. Guerra-Shinohara
Journal: Blood (2004)
Prognostic Impact of VH Gene Mutational Status and CD38 Expression in Japanese CLL Patients.
Authors: Hiromi Koiso, Masamitsu Karasawa, Arito Yamane, Takeki Mitsui, Takafumi Matsushima, Norifumi Tsukamoto, Hirokazu Murakami, Syuichi Miyawaki, Yoshihisa NOjima
Journal: Blood (2004)
Proteomic Analysis of Reprograming of Mesenchymal Stem/Stromal Cells (MSC) Following Interferon Gamma Identifies Pathways That Are Upregulated in Suppression
Authors: Qingdong Guan, Tanner Shpiruk, Peyman Ezzati, Oleg Krokhin, Scott Gilpin, James Doerksen, Victor Spicer, Swaroop Bhagwat, John Wilkins, Donna A. Wall
Journal: Blood (2015)
Green Tea Extract EGCG Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells Through the Regulation of PI3K/Akt Cascade and Proteasome Activity
Authors: Elena Ponath, Susanne Schnabl, Martin Hilgarth, Dita Demirtas, Marlies Reiter, Eva Fuchs, Rainer Hubmann, Ulrich Jäger, Medhat Shehata
Journal: Blood (2012)
Association of a Frailty Screening Initiative With Postoperative Survival at 30, 180, and 365 Days
Authors: Daniel E. Hall, Shipra Arya, Kendra K. Schmid, Mark A. Carlson, Pierre Lavedan, Travis L. Bailey, Georgia Purviance, Tammy Bockman, Thomas G. Lynch, Jason M. Johanning
Journal: JAMA Surgery (2016)

<h3>Importance</h3> As the US population ages, the number of operations performed on elderly patients will likely increase. Frailty predicts postoperative mortality and morbidity more than age alone, thus presenting opportunities to identify the highest-risk surgical patients and improve their outcomes. <h3>Objective</h3> To examine the effect of the Frailty Screening Initiative (FSI) on mortality and complications by comparing the surgical outcomes of a cohort of surgical patients treated before and after implementation of the FSI. <h3>Design, Setting, and Participants</h3> This single-site, facility-wide, prospective cohort quality improvement project studied all 9153 patients from a level 1b Veterans Affairs medical center who presented for major, elective, noncardiac surgery from October 1, 2007, to July 1, 2014. <h3>Interventions</h3> Assessment of preoperative frailty in all patients scheduled for elective surgery began in July 2011. Frailty was assessed with the Risk Analysis Index (RAI), and the records of all frail patients (RAI score, ≥21) were flagged for administrative review by the chief of surgery (or designee) before the scheduled operation. On the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient's frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input. <h3>Main Outcomes and Measures</h3> Postoperative mortality at 30, 180, and 365 days. <h3>Results</h3> From October 1, 2007, to July 1, 2014, a total of 9153 patients underwent surgery (mean [SD] age, 60.3 [13.5] years; female, 653 [7.1%]; and white, 7096 [79.8%]). Overall 30-day mortality decreased from 1.6% (84 of 5275 patients) to 0.7% (26 of 3878 patients,<i>P</i> &lt; .001) after FSI implementation. Improvement was greatest among frail patients (12.2% [24 of 197 patients] to 3.8% [16 of 424 patients],<i>P</i> &lt; .001), although mortality rates also decreased among the robust patients (1.2% [60 of 5078 patients] to 0.3% [10 of 3454 patients],<i>P</i> &lt; .001). The magnitude of improvement among frail patients increased at 180 (23.9% [47 of 197 patients] to 7.7% [30 of 389 patients],<i>P</i> &lt; .001) and 365 days (34.5% [68 of 197 patients] to 11.7% [36 of 309 patients],<i>P</i> &lt; .001). Multivariable models revealed improved survival after FSI implementation, controlling for age, frailty, and predicted mortality (adjusted odds ratio for 180-day survival, 2.87; 95% CI, 1.98-4.16). <h3>Conclusions and Relevance</h3> Implementation of the FSI was associated with reduced mortality, suggesting the feasibility of widespread screening of patients preoperatively to identify frailty and the efficacy of system-level initiatives aimed at improving their surgical outcomes. Additional investigation is required to establish a causal connection.
US Democrats’ vs Republicans’ Views on Compensating Living Kidney Donors
Authors: Carlo Maria Rosati
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement.
Authors: John E. Wagner, Akemi Ishida-Yamamoto, John A McGrath, Maria Hordinsky, Douglas R Keene, Mark Osborn, Troy Lund, Michelle Dolan, Bruce R. Blazar, Jakub Tolar
Journal: Blood (2009)
Acquisition of Cytogenetic Abnormalities (CA) Is a Very Poor Prognostic Feature in Patients (pts) with Low and Intermediate-1 (int-1) Risk Myelodysplastic Syndromes (MDS),
Authors: Elias Jabbour, Hagop M. Kantarjian, Xuemei Wang, Lynne V. Abruzzo, A Megan Cornelison, Susan O'Brien, Farhad Ravandi, Tapan Kadia, Gautam Borthakur, Zeev Estrov, Jorge E. Cortes, Guillermo Garcia-Manero
Journal: Blood (2011)
Association Between Inpatient Sleep Loss and Hyperglycemia of Hospitalization
Authors: Regina H. DePietro, Kristen L. Knutson, Lisa Spampinato, Samantha L. Anderson, David O. Meltzer, Eve Van Cauter, Vineet M. Arora
Journal: Diabetes Care (2016)

OBJECTIVE To determine whether inpatient sleep duration and efficiency are associated with a greater risk of hyperglycemia in hospitalized patients with and without diabetes. RESEARCH DESIGN AND METHODS In this retrospective analysis of a prospective cohort study, medical inpatients ≥50 years of age were interviewed, and their charts were reviewed to obtain demographic data and diagnosis. Using World Health Organization criteria, patients were categorized as having normal blood glucose, impaired fasting blood glucose, or hyperglycemia based on morning glucose from the electronic health record. Wrist actigraphy measured sleep. Multivariable ordinal logistic regression models, controlling for subject random effects, tested the association between inpatient sleep duration and proportional odds of hyperglycemia versus impaired fasting blood glucose or impaired fasting blood glucose versus normal blood glucose in hospitalized adults. RESULTS A total of 212 patients (60% female and 74% African American) were enrolled. Roughly one-third (73, 34%) had diabetes. Objective inpatient sleep measures did not differ between patients with or without diabetes. In ordinal logistic regression models, each additional hour of in-hospital sleep was associated with an 11% (odds ratio 0.89 [95% CI 0.80, 0.99]; P = 0.043) lower proportional odds of a higher glucose category the next morning (hyperglycemia vs. elevated and elevated vs. normal). Every 10% increase in sleep efficiency was associated with an 18% lower proportional odds of a higher glucose category (odds ratio 0.82 [95% CI 0.74, 0.89]; P &amp;lt; 0.001). CONCLUSIONS Among medical inpatients, both shorter sleep duration and worse sleep efficiency were independently associated with greater proportional odds of hyperglycemia and impaired fasting glucose.
In Vitro and Vivo Activity Against Multiple Myeloma Cells Of a Novel Locked Nucleic Acid (LNA)-Mir-221 Inhibitor
Authors: Maria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio, Emanuela Altomare, Nicola Amodio, Emanuela Leone, Santo Giovanni Lio, Eugenio Morelli, Daniele Caracciolo, Cirino Botta, Antonino Neri, Niels M Frandsen, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood (2013)
Use of a fully covered metal stent to treat obstruction of the minor papilla in pancreas divisum
Authors: Alexander Hann, Benjamin Walter, Alexander Meining
Journal: Endoscopy (2016)

A 70-year-old woman was admitted with an episode of epigastric pain radiating into her back, accompanied by intermittent nausea and vomiting. Acute pancreatitis was diagnosed and transabdominal ultrasound revealed a dilated pancreatic duct of 6 mm due a ductal stone.
Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients with Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy: Toxicity Comparison of Two Dose Schedules
Authors: Jesus G. Berdeja, Michael R. Savona, James Essell, Patrick Murphy, Luis Chu, Ralph V. Boccia, Edward Arrowsmith, Ian W. Flinn
Journal: Blood (2012)
Results of a Phase 2 Study of MEDI-551 and Bendamustine Vs Rituximab and Bendamustine in Relapsed or Refractory Chronic Lymphocytic Leukemia
Authors: Douglas Gladstone, Marc Andre, Jan Zaucha, Sarit Assouline, Naresh Bellam, Nicole Cascavilla, Eric Jourdan, Amit Panwalkar, Caterina Patti, Clemens Schulte, Francesco Zaja, Trishna Goswami, Nairouz Elgeioushi, Katie Streicher, Haifeng Bao, David Spaner
Journal: Blood (2014)
Targeted Repression of TP53 Promotes Erythropoiesis in Del(5q) MDS and Overcomes Clinical Resistance to Lenalidomide
Authors: Gisela Caceres, Joe Johnson, Kathy L. McGraw, Ashley A. Basiorka, Kenian Liu, Larry J Smith, F. Joseph Daugherty, Sheng Wei, Rami S. Komrokji, Ling Zhang, Neil Littleton, Richard A. Wells, Lubomir Sokol, Alan F List
Journal: Blood (2012)
Symptoms and Signs of Hemochromatosis in HFE C282Y Homozygotes Identified by Screening in Primary Care.
Authors: Gordon D. McLaren, Christine E. McLaren, Paul C. Adams, James C. Barton, David M. Reboussin, Victor R. Gordeuk, Ronald T. Acton, Emily L. Harris, Mark Speechley, Phyliss Sholinsky, Fitzroy W. Dawkins, Beverly M. Snively, Thomas Vogt, John H. Eckfeldt
Journal: Blood (2006)
Expression of Wnt-Inhibitors and SDF-1 in Whole Bone Marrow Biopsies in Association to the Osteolytic Bone Disease of Multiple Myeloma.
Authors: Ida Bruun Kristensen, Jacob Haaber, Maria B Lyng, Lise Pedersen, Lars Melholt Rasmussen, Henrik J Ditzel, Niels Abildgaard
Journal: Blood (2012)
Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML): Low Incidence of Relapse and Graft Versus Host Disease (GVHD) in Patients (pts) Transplanted without Active Leukemia Using in-Vivo T-Cell Depletion with Rabbit Anti-Thymocyte Globulin (r-ATG)
Authors: James L. Slack, Jose F. Leis, Craig B. Reeder, Joseph R. Mikhael, Raoul Tibes, Pierre Noel, Ruben A. Mesa, Jeffrey A. Betcher, Mary E Peterson, Meagan S. Higgins, Ginger Gillette-Kent, Lisa D. Tremblay, Jane J Olsen, Roberta H. Adams
Journal: Blood (2011)
The draft genome of the C3 panicoid grass species Dichanthelium oligosanthes
Authors: Anthony J. Studer, James C. Schnable, Sarit Weissmann, Allison R. Kolbe, Michael R. McKain, Ying Shao, Asaph B. Cousins, Elizabeth A. Kellogg, Thomas P. Brutnell
Journal: Genome biology (2016)

Comparisons between C3 and C4 grasses often utilize C3 species from the subfamilies Ehrhartoideae or Pooideae and C4 species from the subfamily Panicoideae, two clades that diverged over 50 million years ago. The divergence of the C3 panicoid grass Dichanthelium oligosanthes from the independent C4 lineages represented by Setaria viridis and Sorghum bicolor occurred approximately 15 million years ago, which is significantly more recent than members of the Bambusoideae, Ehrhartoideae, and Pooideae subfamilies. D. oligosanthes is ideally placed within the panicoid clade for comparative studies of C3 and C4 grasses. We report the assembly of the nuclear and chloroplast genomes of D. oligosanthes, from high-throughput short read sequencing data and a comparative transcriptomics analysis of the developing leaf of D. oligosanthes, S. viridis, and S. bicolor. Physiological and anatomical characterizations verified that D. oligosanthes utilizes the C3 pathway for carbon fixation and lacks Kranz anatomy. Expression profiles of transcription factors along developing leaves of D. oligosanthes and S. viridis were compared with previously published data from S. bicolor, Zea mays, and Oryza sativa to identify a small suite of transcription factors that likely acquired functions specifically related to C4 photosynthesis. The phylogenetic location of D. oligosanthes makes it an ideal C3 plant for comparative analysis of C4 evolution in the panicoid grasses. This genome will not only provide a better C3 species for comparisons with C4 panicoid grasses, but also highlights the power of using high-throughput sequencing to address questions in evolutionary biology.
Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring.
Authors: Toni K. Choueiri, Esteban Walker, Rachid C. Baz, Rony M. Abou-Jawde, Snehal G. Thakkar, Bridget McGowan, Megan Kelly, Steven Andresen, Mohamad Hussein
Journal: Blood (2005)